Commercially marketed CBD-infused products are not subject to explicit federal regulations. As a result, third-party lab testing has frequently revealed inconsistencies between the percentage of CBD advertised and the amount actually contained in some of these products.
Last week, NORML leaders and activists from across North America headed to our nation’s capital for the annual NORML Conference and Congressional Lobby Day.
This year the Texas delegation at the 2019 NORML Conference and Lobby Day grew exponentially! We had a group of seven advocates that made the trip up to Washington, DC.
Rather than use these unfortunate incidents as an opportunity to further drive these markets into the shadows, the administration should officially legalize cannabis and empower the FDA to better study, regulate, and oversee these emerging THC and CBD delivery devices — and to create regulatory standards for legal states to follow and enforce.
Proponents of a 2020 statewide ballot measure to legalize and regulate medical cannabis access have submitted 105,686 signatures to the Secretary of State’s office. A spokesperson for the group backing the campaign, Mississippians for Compassionate Care, said that the measure “polls above 77 percent, with [majority support from] every age group, religious affiliation, [and] political affiliation.”
The US Centers for Disease Control has now identified over 450 cases of respiratory distress that may be associated with the use of disposable vapor cartridges used to consume certain e-liquids.